For media inquiries, please contact Erich Horsley at: media@biosplice.com

2024

Date	Title
Sep 12	Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
Jun 13	Biosplice Announces Collaboration with Novo Nordisk in Diabetes
Apr 18	Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function Results for Lorecivivint for Treatment of Knee Osteoarthritis at OARSI Conference, and Completion and Preliminary Analysis of OA-21 Trial 12-Week Pain Results
Mar 08	Biosplice Therapeutics Announces Department of Defense Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program

2023

Date	Title
Nov 13	Biosplice Presents Successful Structure and Pain Results from Completed Phase 3 Long-Term Extension Clinical Trial for Lorecivivint for the Treatment of Knee Osteoarthritis

2022

Date	Title
Nov 11	Biosplice Announces Data from Recent Clinical Trials in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial
Sep 09	Biosplice Therapeutics Announced New Clinical Data for Cirtuvivint (SM08502) at the European Society for Medical Oncology Meeting

2021

Date	Title
Nov 17	First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology
Sep 15	Biosplice Licenses Development and Commercialization Rights for Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Haisco for the People’s Republic of China
Sep 15	FierceBiotech: Haisco to Pay $140M to Get the Ball rolling on Biosplice's Phase 3 Osteoarthritis Drug in China
Jul 22	Biosplice Publishes Phase 2B Lorecivivint Analysis Showing Clinically Meaningful Benefits to Knee Osteoarthritis Patients
Jun 21	Dave Johnson Joins Biosplice Therapeutics Board of Directors
Apr 26	Biosplice Publishes Successful Clinical Trial in Knee Osteoarthritis
Apr 22	Biosplice Licenses Rights to Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Samil for the Republic of Korea
Apr 20	Biotech Veterans Troy Cox, Susannah Gray and Karen McGinnis Join Biosplice Therapeutics Board of Directors
Apr 15	Biosplice Therapeutics Closes $120 Million in Equity Financing to Advance its Alternative Splicing Platform

2020

Date	Title
Dec 01	Darrin M. Beaupre, M.D., Ph.D. joins Biosplice as Chief Medical Officer, Oncology
Nov 17	Biosplice Chief Medical Officer, Dr. Yusuf Yazici, Discusses Lorecivivint on the Podcast “ACR on Air”
Jun 01	Michael White, Ph.D. joins Biosplice as Chief Scientific Officer
May 22	Biosplice Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis
Jan 23	Rheumatology Advisor: Effect of Intra-Articular Treatment on Patient-Reported Outcomes in Knee Osteoarthritis
Jan 21	BioSpace: Getting to the Root of the Disease: Developing Drugs Against the Hard-to-Target Wnt Pathway
Jan 06	DDNews: Meeting a new mechanism

Web Analytics